載入中
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
前收盤價
US$1.08
−US$0.03 · -2.70%
盤中時間採用ET。市場資料可能有所延遲。
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
日內區間
目前US$1.08
52週區間
目前US$1.08
盤中時間採用ET。市場資料可能有所延遲。
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
日內區間
目前US$1.08
52週區間
目前US$1.08
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（AUD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 754.5萬 AUD | 728.7萬 AUD | 490.29萬 AUD | 180.47萬 AUD | 76.52萬 AUD |
| 銷貨成本 | 267.87萬 AUD | 252.19萬 AUD | 156.61萬 AUD | 6.46萬 AUD | 24.17萬 AUD |
| 毛利 | 486.64萬 AUD | 476.51萬 AUD | 333.68萬 AUD | 174.01萬 AUD | 52.35萬 AUD |
| 研究與開發 | — | 359.73萬 AUD | 537.55萬 AUD | 259.21萬 AUD | 65.77萬 AUD |
| 銷售、一般及管理費用 | 760.72萬 AUD | 793.6萬 AUD | 658.54萬 AUD | 514.83萬 AUD | 394.09萬 AUD |
| 營業費用 | 949.84萬 AUD | 1010.96萬 AUD | 913.79萬 AUD | 530.89萬 AUD | 339.34萬 AUD |
| 利息收入 | — | 13.59萬 AUD | 32.78萬 AUD | 11.63萬 AUD | 2.18萬 AUD |
| 利息支出 | 1.44萬 AUD | 7305 AUD | 7576 AUD | 9652 AUD | 6184 AUD |
| 折舊和攤銷 | — | 4.97萬 AUD | 4.42萬 AUD | 4.87萬 AUD | 2.66萬 AUD |
| 營業利益 | −463.2萬 AUD | −534.45萬 AUD | −580.11萬 AUD | −356.88萬 AUD | −286.99萬 AUD |
| 淨利 | −375.48萬 AUD | −521.6萬 AUD | −693.7萬 AUD | −378.65萬 AUD | −285.43萬 AUD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
